Broadfin Capital’s AbbVie ABBV Stock Holding History

Broadfin Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-154,500	Closed	-$11.7M	–	41
2019 Q3	$11.7M	Buy	+154,500	New	+$10.6M	2.16%	16

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Broadfin Capital's ABBV Position: Q4 2019 in Review

Broadfin Capital sold out of AbbVie (ABBV) in Q4 2019, closing a stake of 154,500 shares — an estimated $11.7M sold.

Broadfin Capital first reported a position in ABBV in Q3 2019 and held it in 1 quarter. The position peaked at $11.7M in Q3 2019. 2,243 funds tracked by Wall St. Rank hold ABBV as of Q4 2019.

Broadfin Capital reported no remaining AbbVie position as of Q4 2019 after selling out during the quarter.
Broadfin Capital sold 154,500 AbbVie shares in Q4 2019, an estimated $11.7M.
Broadfin Capital first reported a position in AbbVie in Q3 2019 and held it in 1 quarter.
Broadfin Capital's AbbVie position peaked at $11.7M in Q3 2019.
2,243 funds tracked by Wall St. Rank held AbbVie as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.